BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Total Current Liabilities
All obligations due within one year.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 79.8% from a year ago
Total current liabilities stood at $43.26M at the end of Q1 FY2026, up 79.8% from a year earlier and up 23.5% from the prior quarter. Over 3 fiscal years it compounded at +494.9% a year.
Context
- Total current liabilities amounted to 10.4% of total assets at the end of Q1 FY2026, down 5.7 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +79.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 35.04M USD
- Year-over-year change
- +18587.0%
- 4-year CAGR
- +283.1%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.04M | +18587.0% |
| FY2024 | 2024-12-31 | 187.52K | -52.7% |
| FY2023 | 2023-12-31 | 396.46K | +138.2% |
| FY2022 | 2022-12-31 | 166.46K | +2.3% |
| FY2021 | 2021-12-31 | 162.64K | — |
Total Current Liabilities vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +79.8% is the highest of 10, against a peer median of +29.0%.
- Total current liabilities amounts to 10.4% of total assets for BBOT, versus a peer median of 16.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $130.74M USD | +58.8% | +7.0% | 10.9% | |
| Mar 2026 | $125.04M USD | +68.9% | +71.4% | 41.0% | |
SEPNSepterna, Inc. | Sep 2026 | $104.86M USD | +39.3% | +150.3% | 16.9% |
| Jun 2026 | $81.87M USD | -14.8% | +14.5% | 11.3% | |
| Sep 2026 | $54.74M USD | +29.0% | -4.6% | 26.1% | |
| Mar 2026 | $50.64M USD | +20.6% | +24.7% | 20.0% | |
| Mar 2026 | CHF 43.73M CHF | +10.8% | +45.2% | 18.0% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $43.26M USD | +79.8% | +494.9% | 10.4% |
| Mar 2026 | $41.7M USD | -5.3% | +14.0% | 12.6% | |
| Sep 2026 | $25.16M USD | +36.4% | -26.9% | 2.4% | |
| Peer median (excluding BBOT) | — | +29.0% | +14.5% | 16.9% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.